$10.66
arrow_drop_down3.52%Based on the fundamental analysis of Walgreens Boots Alliance, the company has a healthy dividend yield of 5.77%, which is a significant factor for income investors looking for stable returns. Additionally, the company's price-to-earnings ratio (P/E) is not available, but the price-to-sales ratio of 0.11 indicates that the stock may be undervalued relative to its revenue. Furthermore, the company's price-to-book ratio of 1.14 suggests that the stock is trading close to its book value, which could be attractive for value investors. Moreover, the enterprise value to EBITDA ratio of -4.31 indicates that the company's profitability is strong. On the other hand, Walgreens Boots Alliance's return on equity (ROE) of -57.19% is concerning as it indicates that the company is not effectively generating profits from shareholders' equity. Additionally, the company's net margin and pre-tax margin are not available, which could signal a lack of transparency in the company's financial reporting. Furthermore, the company's high level of debt, with a debt-to-equity ratio of 2.25, raises concerns about the company's ability to service its debt obligations in the long term. Overall, investors should consider these key fundamental indicators carefully before making any investment decisions in Walgreens Boots Alliance.
Walgreens Boots Alliance has declared a quarterly dividend, which indicates a positive outlook on the company's financial performance and stability. The company has received attention from Zacks.com users, suggesting a potential increase in investor interest and market recognition. The company has launched a specialty pharmacy unit to compete in the new PBM era, which indicates a proactive approach towards adapting to market changes and improving its competitive position.
The company has been facing legal issues over online tracking technologies, which may impact its reputation and potential legal liabilities. The company's pre-tax margin is negative, indicating potential financial instability. The company's long-term debt to total asset ratio is high, which could create financial difficulties in the future.
Walgreens Boots Alliance (WBA) currently has a technical rating of NEUTRAL based on various indicators. In the past month, the stock has shown 3 technical buy signals, including Commodity Channel Index (CCI), Average True Range (ATR), and Williams %R (WILLR). Additionally, there are 5 technical hold indicators in place, such as Relative Strength Index (RSI), Moving Average Convergence Divergence (MACD), Average Directional Index (ADX), Rate of Change (ROC), and Stochastic Relative Strength Index (StochRSI). These indicators suggest that the stock may be experiencing a period of consolidation or uncertainty in its price movement. Furthermore, Walgreens Boots Alliance's stock is currently trading below its longest trendline, which has a downward slope. The trendline analysis indicates that the stock price has been on a decline since the beginning of the year, with a forecasted price of $19.55 by May 6th. This downward trend is reflective of the stock's performance over the past few months, with negative price changes in the seven days, one month, three months, six months, year-to-date, and five years periods. With a technical rating of NEUTRAL and a downward trendline, investors may want to closely monitor WBA's price movement and consider the implications for their investment decisions.
Based on the data provided, Walgreens Boots Alliance (WBA) is a healthcare company with a market cap of $15.3B and 200K employees. The company has a dividend yield of 5.77% and a trailing annual dividend yield of 5.54%, indicating a strong commitment to returning value to shareholders. However, with a negative trailing PE ratio of -2.54%, a negative return on equity of -57.19%, and a negative net income of -$3.53B, there are clear financial challenges that need to be addressed. The company also has a high debt-to-equity ratio of 2.25, which may indicate financial risk. In conclusion, Walgreens Boots Alliance shows potential for growth with a positive analyst forecast price change of 27.51% and a strong industry value score of 27. However, the company faces significant financial challenges such as negative earnings growth, low profitability, and high debt levels. Investors should carefully monitor the company's efforts to improve its financial performance, reduce debt, and increase profitability before considering an investment. Overall, while the company's dividend yield may be attractive, caution is advised due to the company's current financial health and challenges.